Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Olivier Brandicourt
AddedFeb 13, 2024
UpdatedMay 31, 2026
Olivier Brandicourt

Olivier Brandicourt

Board Member, Dewpoint Therapeutics

The Org

Olivier Brandicourt's Career

Dewpoint Therapeutics
Dewpoint Therapeutics

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Olivier Brandicourt's Career

Dewpoint Therapeutics
Dewpoint Therapeutics
Series C$287M1612018Boston, MA, US
Board Member· Board

Leadership at Dewpoint Therapeutics

Jürgen EckhardtJürgen EckhardtBoard Member
Giuseppe CiaramellaGiuseppe CiaramellaBoard Member
Ameet NathwaniAmeet NathwaniCEO
Mark MurckoMark MurckoBoard Member
Amir NashatAmir NashatBoard Member
Richard YoungRichard YoungCo-Founder

Similar to Dewpoint Therapeutics

Faze MedicinesFaze MedicinesCambridge, MA, USTherapeuticsest. 2020Faze MedicinesCambridge, MA, US · est. 2020

Faze Medicines: A pioneering biotech company specializing in biomolecular condensate therapeutics.

Series A · $81M40
Transition BioTransition BioCambridge, MA, USDrug Discoveryest. 2020Transition BioCambridge, MA, US · est. 2020

Transition Bio: Pioneering biomolecular condensate analysis tech for precise drug discovery.

Series A · $50M50
DeepBiome TherapeuticsDeepBiome TherapeuticsLlanura, MA, USDrug Discoveryest. 2017DeepBiome TherapeuticsLlanura, MA, US · est. 2017

DeepBiome Therapeutics, a US-based biotech firm, leverages deep learning and synthetic biology for innovative drug discovery.

Seed · $2.5M6
Nereid TherapeuticsNereid TherapeuticsBoston, MA, USDrug Discoveryest. 2020Nereid TherapeuticsBoston, MA, US · est. 2020

Nereid Therapeutics: Innovating drug discovery with proprietary technologies for new disease treatments.

Series A · $50M12

Olivier Brandicourt's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Olivier Brandicourt

John DeYoungJohn DeYoungBoard Member · Allogene TherapeuticsDenis PatrickDenis PatrickBoard Member · Palleon PharmaceuticalsHabib DableHabib DableBoard Member · Blueprint MedicinesRichard MarounRichard MarounBoard Member · Whitehawk TherapeuticsChris RamsborgChris RamsborgBoard Member · Inceptor BioDieter WeinandDieter WeinandBoard Member · HealthPrize Technologies